Evidence map›Paper›PMID 34484888›Full record

ArticleNeurology. Clinical practice2021

Health Care Utilization and Costs in Patients With Migraine Who Have Failed Previous Preventive Treatments.

Lawrence Newman, Pamela Vo, Lujia Zhou, Cristina Lopez Lopez, Andy Cheadle, Melvin Olson, Juanzhi Fang

Open access · greenAbstract read
In one paragraph

Article in Neurology. Clinical practice, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Migraine management in Saudi Arabia: An expert consensus.Neurosciences (Riyadh, Saudi Arabia) · 2025
    Guideline
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Lawrence NewmanHeadache Division (LW), NYU Langone Medical Center, NY; Novartis Pharma AG (PV, CLL, MO), Basel, Switzerland; KMK Consulting Inc. (LZ), Morristown, NJ; and Novartis Pharmaceuticals Corporation (AC, JF), East Hanover, NJ.
Pamela VoHeadache Division (LW), NYU Langone Medical Center, NY; Novartis Pharma AG (PV, CLL, MO), Basel, Switzerland; KMK Consulting Inc. (LZ), Morristown, NJ; and Novartis Pharmaceuticals Corporation (AC, JF), East Hanover, NJ.
Lujia ZhouHeadache Division (LW), NYU Langone Medical Center, NY; Novartis Pharma AG (PV, CLL, MO), Basel, Switzerland; KMK Consulting Inc. (LZ), Morristown, NJ; and Novartis Pharmaceuticals Corporation (AC, JF), East Hanover, NJ.
Cristina Lopez LopezHeadache Division (LW), NYU Langone Medical Center, NY; Novartis Pharma AG (PV, CLL, MO), Basel, Switzerland; KMK Consulting Inc. (LZ), Morristown, NJ; and Novartis Pharmaceuticals Corporation (AC, JF), East Hanover, NJ.
Andy CheadleHeadache Division (LW), NYU Langone Medical Center, NY; Novartis Pharma AG (PV, CLL, MO), Basel, Switzerland; KMK Consulting Inc. (LZ), Morristown, NJ; and Novartis Pharmaceuticals Corporation (AC, JF), East Hanover, NJ.
Melvin OlsonHeadache Division (LW), NYU Langone Medical Center, NY; Novartis Pharma AG (PV, CLL, MO), Basel, Switzerland; KMK Consulting Inc. (LZ), Morristown, NJ; and Novartis Pharmaceuticals Corporation (AC, JF), East Hanover, NJ.
Juanzhi FangHeadache Division (LW), NYU Langone Medical Center, NY; Novartis Pharma AG (PV, CLL, MO), Basel, Switzerland; KMK Consulting Inc. (LZ), Morristown, NJ; and Novartis Pharmaceuticals Corporation (AC, JF), East Hanover, NJ.
Novartis (Switzerland) · CHNYU Langone Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo characterize health care utilization (HCU) and associated costs among patients with migraine categorized by the number of preventive treatment failures (TFs; 1 TF, 2 TFs, and 3+ TFs) using real-world data.

methodsThis retrospective analysis identified adults with incident migraine diagnosis in the IBM MarketScan Commercial and Medicare Supplemental database between January 1, 2011, and June 30, 2015. TF was defined in the 2 years after the first migraine diagnosis period. One TF, 2 TFs, and 3+ TFs were defined as patients who had received only 2 preventive treatments (PTs), 3 PTs, and 4+ PTs in the 2-year period, respectively. A negative binomial model was used to analyze HCU data, and a 2-part model was used for cost data controlling for the preindex Deyo-Charlson Comorbidity Index.

resultsOverall, 24,282 patients with incident migraine who had failed at least 1 PT were included in the analysis. Of these, 72.7% (n = 17,653) had 1 TF, 20.2% (n = 4,900) had 2 TFs, and 7.1% (n = 1,729) had 3+ TFs. Adjusted annualized rates of all-cause and migraine-specific HCU increased with an increase in the number of TFs (1.4-4 times higher; all

conclusionsTF in patients with migraine was associated with a substantial resource and cost burden, which increased with the number of TFs.

Identifiers

PMID34484888
PMCPMC8382370
OpenAlexW3144178347

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.